Protein tyrosine phosphatase-g (PTP-g) is a receptor-like PTP whose biological function is poorly understood. A recent mouse PTP-g genetic deletion model associated the loss of PTP-g gene expression with a potential antidepressant phenotype. This led the authors to screen a subset of the Bristol-Myers Squibb (BMS) compound collection to identify selective smallmolecule inhibitors of receptor-like PTP-g (RPTP-g) for use in evaluating enzyme function in vivo. Here, they report the design of a high-throughput fluorescence resonance energy transfer (FRET) assay based on the Z′-LYTE technology to screen for inhibitors of RPTP-g. A subset of the BMS diverse compound collection was screened and several compounds identified as RPTP-g inhibitors in the assay. After chemical triage and clustering, compounds were assessed for potency and selectivity by IC 50 determination with RPTP-g and two other phosphatases, PTP-1B and CD45. One hundred twenty-nine RPTP-g selective (defined as IC 50 value greater than 5-to 10-fold over PTP-1B and CD45) inhibitors were identified and prioritized for evaluation. One of these hits, 3-(3, 4-dichlorobenzylthio) thiophene-2-carboxylic acid, was the primary chemotype for the initiation of a medicinal chemistry program. (Journal of Biomolecular Screening 2011;16;476-485) 
INTRODUCTION
P rotein tyrosine phosphatases (ptps) and protein tyrosine kinases are responsible for regulating intracellular protein tyrosine phosphorylation states. Protein tyrosine phosphorylation can alter protein-protein interactions and enzymatic activity in signaling cascades. Defective or inappropriate regulation of PTP activity leads to aberrant tyrosine phosphorylation, which contributes to the development of diseases such as cancer and diabetes. 1 PTPs can be further classified as intracellular PTPs or receptor-like PTPs (RPTPs) based on their cellular localization. The receptor-like PTPs such as PTPa and CD45 have several domains, including an extracellular domain, putative ligandbinding domain, a single-transmembrane region, and one or two cytoplasmic phosphatase domains. Intracellular PTPs such as PTP1B and SHP-2 contain a single catalytic domain and various amino or carboxylic terminal extensions, which may have targeting or regulatory functions. 2 RPTP-g is a receptor-type PTP containing an extracellular carbonic anhydrase-like domain. 3 The carbonic anhydrase-like domain is also present in the related RPTP, RPTP-z (also designated b), and together they define a RPTP subfamily. RPTP-g exists in four isoforms, termed A-D. 4 The RPTP-g-B isoform is missing 29 amino acids from the intracellular juxtamembrane region present in the full-length RPTP-g-A form. RPTP-g-C contains only the proximal PTP domain, whereas RPTP-g-D is a secreted extracellular domain fragment. Like the related RPTP-z, RPTP-g is strongly expressed in the nervous system. RPTP-g mRNA is enriched in pyramidal and sensory neurons and sensory organs. 5 Relatively few studies have been published regarding the function of RPTP-g.
Overexpression of RPTP-g-A in PC12D cells has been reported to prevent neurite outgrowth induced by nerve growth factor (NGF) treatment. 6 A recent RPTP-g genetic knockout study has reported normal development in the null mice. 5 The authors report deficits in motor coordination and enhanced prepulse inhibition, which they speculate may be due to alterations in the vestibulocochlear system. In addition, they observe enhanced latency to first immobilization in the tail suspension test (a model frequently used to evaluate potential antidepressant activity). These data suggest that inhibition of RPTP-g activity by a small molecule could be a strategy for developing a novel antidepressant. To determine if this phenotype could be reproduced with a small molecule, it was necessary to identify an appropriate tool compound. We designed a high-throughput assay for RPTP-g inhibition using the Z′-LYTE Technology to screen a portion of the Bristol-Myer Squibb (BMS) compound collection. Although the Z′-LYTE Technology is typically used for kinase assays, we demonstrate that the system can be modified and used for identification of phosphatase inhibitors.
The Z′-LYTE is a fluorescence resonance energy transfer (FRET)-based, coupled-enzyme assay that uses the differential sensitivity of phosphorylated and nonphosphorylated peptides to proteolytic cleavage. The phosphorylated peptide substrate (p-Tyr 1) is labeled with coumarin (donor) and fluorescein (acceptor) at the N-and C-terminals, respectively, to make up a FRET pair ( Fig. 1 ). In the primary reaction, the phosphatase cleaves the tyrosine phosphate group (Pi) of the substrate, making it susceptible to site-directed proteolytic cleavage in the secondary reaction. Cleavage disrupts FRET between the donor and the acceptor fluorophores on the peptide, whereas uncleaved, phosphorylated peptide maintains FRET. 7 Reaction progress is quantitated by calculating the emission ratio of donor and acceptor emission signals at 465 nm and 535 nm, respectively. A high emission ratio is obtained if the FRET peptide is nonphosphorylated (i.e., phosphatase reaction occurs); however, the emission ratio remains low if the FRET peptide is phosphorylated (i.e., when phosphatase inhibition occurs).
Here, we describe the development of a low-volume 384well Z′-LYTE assay and its use to screen a subset of the BMS compound collection for RPTP-g inhibitors. We identified several RPTP-g inhibitor chemotypes that were selective against two other phosphatases, PTP-1B and CD45. Finally, one of the lead compounds selected for further evaluation was the primary chemotype for the initiation of a medicinal chemistry program.
MATERIALS AND METHODS

Reagents
The assay buffer consisted of 25 mM MOPS (pH 7.0), 50 mM NaCl, 0.5 mM EDTA, 0.5 mM dithiothreitol (DTT), and 0.1% Pluronic F-68. Both the DTT and Pluronic F-68 were added immediately prior to assay initiation. The basic buffer components, MOPS, HEPES, DTT, and all other standard chemicals, including sodium orthovanadate, were purchased from Sigma (St. Louis, MO). The phosphorylated peptide substrate, Z′-LYTE Tyr 1 phosphopeptide (cat. PR4823A), development reagent B (cat. PR5193B), and development buffer B (cat. PR4876C) were purchased from Invitrogen (Carlsbad, CA).
Expression and purification of human recombinant receptor PTP-g
The human receptor PTP-g-B isoform cytoplasmic domain (aa. 790-1445, NCBI accession NM_002841) containing the conservative substitutions V948I and S970T was cloned into a modified pET-28a vector with an upstream His-myc tag. The protein was expressed in BL21 (DE3) bacterial cells. Four liters of starting culture medium (1.5% yeast extract and 2% peptone buffered with 64 mM K/Na phosphate, pH 7.0) in a 10-L fermenter were inoculated with 25 mL of BL21(DE3)-pET28-LG487B-N-HIS culture (50 mL LB plus 50 mg/mL kanamycin inoculated with single colony and incubated at 37 °C overnight [18 h] on a shaker). The cells were allowed to grow at 37 °C until optical density (OD) of 4.5 at 500 nm was reached, and then 200 mL of 10% lactose was added and the temperature reduced to 25 °C. The culture was subsequently fed at 2 mL/min with 800 mL of 10% warm lactose. The cells were harvested ~18 h after lactose induction by centrifugation at 5000 g for 30 min and resuspended in 0.8 to 1.0 L buffer (50 mM Tris, 300 mM NaCl, 10 mM MgCl 2 , 100 mg/mL benzamidine, 50 mg/mL DNase I, 0.1% Tween-20) and cocktail protease inhibitors (Complete Protease Inhibitor Cocktail Tablets, EDTA free; cat. 04 693 132 001; Roche Applied Science,
FIG. 1.
Principles of the Z′-LYTE assay. The Z′-LYTE assay is a fluorescence resonance energy transfer (FRET)-based, coupledenzyme assay that uses the differential sensitivity of phosphorylated and nonphosphorylated peptides to proteolytic cleavage. The phosphorylated peptide substrate (p-Tyr 1) is labeled with coumarin (donor) and fluorescein (acceptor) at N-and C-terminals, respectively, to make up the FRET pair. In the primary reaction, the phosphatase cleaves the tyrosine phosphate group (Pi) of the substrate, making it susceptible to site-directed proteolytic cleavage in the secondary reaction (see figure above). Cleavage disrupts FRET between the donor and the acceptor fluorophores on the peptide, whereas uncleaved, phosphorylated peptide maintains FRET. Reaction progress is quantitated by calculating the emission ratio of donor and acceptor emission signals at 465 nm and 535 nm, respectively. C, coumarin; F, fluorescein; Pi, phosphate. Adopted and modified from Z′-LYTE reagent insert.
Basel, Switzerland). The cells were then lysed using a MicroFluidizer (Microfluidics, Newton, MA) (three passages). The cell lysate was spun at 21K rpm (Beckman JA25.5 rotor; 53,300 g; Beckman-Coulter, Brea, CA) for 20 min. The supernatant was equilibrated with 20 mL of buffer-washed Talon resin (cat. 635502; Clontech, Mountain View, CA) by gentle shaking at 4 °C for 1 h. The resin was washed twice with 100 mL of TBST (Tris-buffered saline plus Tween-20; 50 mM Tris [pH 7.4], 150 mM NaCl, 0.1% Tween-20) after centrifugation and decanting the supernatant. The resin was packed into a high-definition column (2 cm in diameter) and connected to an Akta FPLC (GE Healthcare, Piscataway, NJ) to monitor UV 280 nM. The column was then washed with buffer A (50 mM HEPES, 0.2 M NaCl, 2 mM DTT, and 10 mM imidazole) at 5 mL/min until a baseline was reached (UV 280-nM plateaus; ~5-6 column volumes [100-120 mL]). The protein was eluted by gradient elution from buffer A to 100% buffer B (buffer A plus 250 mM imidazole) over 10 column volumes. Protein fractions were pooled and dialyzed overnight at 4 °C into 20 mM HEPES (pH 8.0), 200 mM NaCl, 5 mM DTT, and 10% glycerol. The dialyzed material was then collected and run on a Superdex 75 10/300 (GE Healthcare) gel filtration column at 1 mL/min with the same dialysis buffer over 1.5 column volumes. Pure fractions were combined and dialyzed overnight at 4 °C into 20 mM HEPES (pH 8.0), 200 mM NaCl, 5 mM DTT, and 40% glycerol. The protein concentration (1.7 mg/mL) was determined by Bradford assay using known quantities of bovine serum albumin as standards. Aliquots of the final product were stored at -80°C.
Receptor PTP-g titration and linearity of dephosphorylation
Receptor PTP-g enzyme and substrate stock solutions were prepared in assay buffer. Final receptor PTP-g enzyme concentrations ranging from 6 to 0.01 nM were evaluated. Each enzyme concentration was tested in triplicate over a time course of 25 min. Assays were carried out at room temperature (25 °C). Assay wells were assembled as follows: 5 mL of the appropriate enzyme stock solution was transferred to a low-volume 384-well black proxiplate (PerkinElmer, Waltham, MA). The reactions were initiated by addition of 5 mL of 2 mM p-Tyr 1 peptide substrate (1 mM final concentration). Individual wells were terminated with 2 mL of 12 mM sodium orthovanadate (2 mM final concentration) at different time points to generate a time course of 0, 2, 5, 10, 15, 20, and 25 min. Wells containing fully phosphorylated and unphosphorylated peptide were included as standards. Finally, 6 mL of proprietary development solution (development reagent B and development buffer B at 1:33 ratio) was added to each well, and the fluorescent emission at 460 nm and 540 nm was measured kinetically (2-min intervals) at room temperature (RT) on the ViewLux imager (PerkinElmer) for 90 min. Progress curves of the development reaction (i.e., protease digestion) were generated from the emission ratios of the fully phosphorylated and unphosphorylated peptide standard wells. The relationship between the emission ratio and dephosphorylation is nonlinear (Z′-LYTE technical data), and therefore the extent of dephosphorylation of the FRET peptide was determined using the following modified form of the % phosphorylation (Z′-LYTE technical data) equation:
where Emission Ratio = coumarin/fluorescein ratio of sample wells, C 100% = average coumarin emission signal of the 100% phosphorylated control, C 0% = average coumarin emission signal of the 0% phosphorylated control, F 100% = average fluorescein emission signal of the 100% phosphorylated control, F 0% = average fluorescein emission signal of the 0% phosphorylated control.
The emission ratios at 60 min were converted to % dephosphorylation using Equation (1). Enzyme titration time courses were plotted using Prism 4.0 (GraphPad Software, La Jolla, CA).
p-Tyr 1 substrate K m determination
The initial reaction rate was determined for 10 pM PTP-g enzyme using the following p-Tyr 1 substrate concentrations: 6, 4, 2, 1, 0.5, and 0.25 mM. Assays were assembled as follow: 5 mL of substrate in assay buffer was transferred into a lowvolume 384-well black proxy plate (PerkinElmer). This was followed by the addition of 5 mL of 20 pM receptor PTP-g enzyme in assay buffer. Replicate sets of the above substrate concentrations were incubated for 2, 4, 8, and 10 min to generate initial rates of reaction. The reactions were terminated with 2 mL of 12 mM orthovanadate (final concentration of 1 mM), followed by the addition of 5 mL of the proprietary development solution. The fluorescent emission at 460 nm and 540 nm was measured on the ViewLux (PerkinElmer) imager after a 60-min incubation at RT. The results were transformed into initial rates, pmol/min of phosphate (Pi), to determine the apparent K m (K m app ) of the p-Tyr 1 substrate and V max of the reaction. The values of the apparent K m and V max were generated by nonlinear fit to the Michaelis-Menton equation using Prism 4.0.
Final high-throughput screening assay conditions
The high-throughput screening (HTS) was performed in a low-volume 384-well black proxiplate (cat. 6007819) purchased from PerkinElmer. The enzyme and substrate were prepared as 2 × concentrates in the assay buffer, 25 mM MOPS (1) (pH 7.0), 50 mM NaCl, 0.5 mM EDTA, 0.5 mM DTT, and 0.1% Pluronic F-68, to achieve a 1 × final concentration when equal volumes were used to initiate the reaction. Pluronic F-68, a nonionic surfactant, was included in the buffer to minimize nonspecific interaction of assay components. The development/stop reagent was made in the development buffer that came with the kit. The assay volumes were reconfigured to 4-mL additions (enzyme, substrate, and development/quench) to achieve a final of 12 mL instead of the 5-mL additions initially used for the design. The phosphatase assay was performed by transferring 4 mL of 60.8 pM enzyme into wells containing 0.1 mL compound (1 mM) in 100% DMSO for a final concentration of 12.3 mM (1.25% DMSO) and preincubated for 10 min at RT. The reaction was initiated by addition of 4 mL of 4 mM p-Tyr 1 substrate. The final enzyme and substrate concentration achieved upon dilution (1:1) were 30 pM and 2 mM, respectively.
The reaction was incubated at RT for 10 min and terminated by the addition of 4 mL of the proprietary development solution, which had been modified to include sodium orthovanadate to stop the reaction. The final concentrations of the development reagent and the sodium orthovanadate were 0.07 mg/mL and 2 mM, respectively. Compounds were preplated using V-prep (Velocity 11, Santa Clara, CA) liquid handler, whereas assay reagents were dispensed by FlexDrop (PerkinElmer) bulk reagent dispenser. The final reaction was allowed to incubate for an additional 1 h at RT, followed by FRET readout at 465 nm (donor fluorescence) and 535 nm (acceptor fluorescence) on the Gen 4 LEADSeeker (GE Healthcare) imager. The results of 0.5-s exposure reads were expressed as the ratios of the fluorescence at 465 nm to 535 nm. It should be noted that the ViewLux (PerkinElmer) imager was used for the assay design, whereas the Gen 4 LEADSeeker imager was used for the HTS, hence the differences in the donor and acceptor emission wavelengths of the readout. However, the emission ratio readouts for both imagers were quantitatively similar.
Selectivity and null assays
Selectivity assays were designed for two other phosphatase enzymes, PTP-1B and CD45. The assay conditions were similar to that of the receptor PTP-g assay described above, with the exception of the concentrations of each enzyme used, which were 50 pM and 0.5 nM for PTP-1B and CD45, respectively. These concentrations were chosen based on the linearity of their respective titration curves and to achieve 20% dephosphorylation in 10 min. These assays were also carried out with 2 mM p-Tyr 1 substrate peptide, which was close to the apparent K m we determined for PTP1B and CD45 (~0.5 mM and ~2 mM, respectively; data not shown).
To rule out assay inference, a null assay was conducted. The assay conditions were the same as the receptor PTP-g assay with the exception of the order of reagent addition. Here, the enzyme and substrate reaction was allowed to proceed for 10 min and quenched with sodium orthovanadate prior to compound addition. The development reagent was subsequently added and incubated for 1 h, followed by FRET readout at 465-nm excitation and 535-nm emission wavelengths.
Screen data management
The LEADSeeker (GE Healthcare) imaging device readout was integrated with an automated data management system. This enabled data quality of control and assay plates to be monitored online in real-time. Subsequent data reduction, analysis, and storage for the primary, retest, and inhibitor concentration response curves (CRCs) were conveniently carried out using an integrated HTS software package developed at BMS. Each plate was imaged twice, with fluorescent emission at 465 nm and 535 nm, and the emission ratio generated as the readout. High (plus enzyme) and low (no enzyme) signal controls on the plates were used to calculate Z′ values 8 during the HTS to monitor assay robustness. Percent inhibition of enzyme activity was subsequently calculated based on the following equation:
% Inhibition = [1 -((compound well ratio -average low control ratio)/(average high control ratio -average low control ratio))] × 100.
To determine inhibitor IC 50 values, % inhibition of the CRCs was fitted to the standard single-site four-parameter logistic equation. It should be noted that the assay was optimized for endpoint readout where the emission ratio was equivalent to 20% dephosphorylation. As a result, the emission ratio values were used for the % inhibition calculations of compound effect and subsequent IC 50 determination, instead of % dephosphorylation, to simplify data analysis.
RESULTS
Assay design and optimization
Prior to optimizing the other components of the RPTP-g assay, it was necessary to determine the time required to complete the coupled peptide digestion reaction. The optimal time was determined by monitoring the progress curves of the protease digestion of the phosphorylated peptide (p-Tyr 1) and the unphosphorylated peptide (Tyr 1) substrates (see Fig. 2 ). The curves were generated following the addition of the stop solution (i.e., 2 mM sodium orthovanadate and 0.07 mg/mL development reagent), and buffer was used in place of receptor PTP-g enzyme to maintain a consistent reaction volume for detection. It was observed that the unphosphorylated peptide substrate was completely digested in 60 min at room temperature, whereas, as expected, the fully phosphorylated peptide was protected and no digestion ensued; therefore, no change in the coumarin/fluorescein emission ratio signal was detected. Hence, assay plates were read after a 60-min incubation with development reagent to ensure maximum digestion. To minimize reagent addition steps during the HTS, the stop reagent (sodium orthovanadate) was combined with the protease development reagent and dispensed together. We confirmed that the addition of sodium orthovanadate did not alter protease digestion progress curve (data not shown). This enabled the primary phosphatase reaction to be quenched while simultaneously initiating the signal development step without adversely affecting the kinetics of the protease reaction.
To determine the enzyme concentration that would generate a linear response of substrate conversion that approximates the initial rate, reaction progress curves were obtained by a sevenpoint titration of the enzyme (Fig. 3A) . The reactions were initiated at different time points to achieve the stated incubation times upon termination. This allowed all reaction wells to be treated alike during the development step. As shown in Figure  3B , a replot of the enzyme titration at the 10-min reaction time, 20% dephosphorylation was achieved at 0.03 nM (30 pM). Under these conditions, the enzyme concentration was in the linear range of the titration curve, and the measured rate of reaction approximated first-order kinetics. The substrate conversion at 10 min (20% dephosphorylation) was adequate to achieve a good signal-to-background ratio and, as a consequence, acceptable Z′ values. Therefore, 30 pM enzyme and 10-min reaction time were chosen for further assay development. For an endpoint assay, the generally accepted practice is to achieve 10% or less substrate conversion, but Wu et al. 9 have shown that, for the purposes of an HTS, under conditions where the reaction progress curve has been demonstrated to follow first-order kinetics, up to 50% substrate conversion will have little effect on the ability to detect weak inhibitors.
We determined the K m app of the p-Tyr 1 peptide by generating initial reaction rates (Fig. 4 ) from the reaction progress curves at different substrate concentrations using 30 pM receptor PTP-g enzyme. The estimated K m app was 5.6 mM (± standard error 0.6) with a corresponding V max and calculated k cat of 3.6 pMole Pi/ min (± standard error 0.2) and 0.12 min -1 , respectively. The values of the apparent K m and V max were generated by nonlinear fit to the Michaelis-Menton equation. We chose 2 mM as the final HTS concentration for p-Tyr 1 peptide, which approximates the estimated K m (i.e., the substrate concentration at which the enzyme reaction achieves half-maximal velocity under steadystate conditions). Under assay conditions where substrate concentration equals K m , there is an equal population of free enzyme (E) and enzyme-substrate (ES) complex available for inhibitor interactions. This condition, referred to as "balanced" with respect to potential enzyme forms, provides the optimal condition to identify diverse types of inhibitors from a screening compound collection. 10, 11 The assay conditions were verified using the optimized parameters to ensure that 20% dephosphorylation was still achieved at 10 min incubation.
DMSO tolerance and enzyme stability
To determine the DMSO tolerance of the PTP-g Z′-LYTE assay, eight-point titrations were made to achieve 0% to 9% final DMSO concentration upon substrate addition. As indicated in Figure 5A , the assay tolerated DMSO up to 1%, followed by a gradual loss of activity from 2% and subsequent higher concentrations. At the highest concentration tested, 9% DMSO, a 40% loss of activity was observed. Subsequently, compounds were screened at 12.3 mM to achieve 1.25% DMSO in the final assay. We determined the thermal stability of the assay reagent (enzyme, substrate, and development reagent) stocks for an automated screening cycle of at least 17 h. These were conducted by leaving prepared stocks of reagents at either 4 °C or room temperature and used immediately (0 h), 1 h, 3 h, and 17 h (overnight). It was observed that, when reagent stocks were left at 4 °C, the assay signal was stable overnight. However, at room temperature, there was a gradual decrease in signal up to ~60% loss overnight (data not shown). As a result, the enzyme, substrate, and development reagent stock solutions were kept at 4 °C during each screening cycle.
Assay validation for HTS
The final assay conditions chosen for the HTS were 30 pM receptor PTP-g enzyme and 2 mM p-Tyr 1 peptide substrate. Compounds (1 mM) were added in 0.1-mL volumes for a final concentration of 12.3 mM (1.25% DMSO). The phosphatase assay was terminated and protease activity initiated using 0.067 mg/mL development reagent and 2 mM orthovanadate. To validate the assay for HTS, duplicate plates of high (with enzyme) and low signal (buffer in place of enzyme) reactions, as well as 10 reference phosphatase inhibitor titrations, were run over 3 consecutive days to determine consistency of assay performance and integrity. Figure 5B shows a typical distribution of high and low signal control reactions (192 wells each).
There was robust signal separation with signal to background of ~8 and Z′ of 0.8. The overall coefficients of variation (CVs) associated with both the high and low signal controls were observed to be approximately 3%. These statistics were consistent over the three consecutive runs. The reference phosphatase inhibitors generated IC 50 values that were also consistent over the three consecutive runs. Figure 6A,B shows sample concentration response curves for 2 of the 10 inhibitors that were considered, compound 1 and compound 2, with IC 50 values of 0.73 mM and 9.06 mM, respectively. Titrations of the 10 reference FIG. 6. Sample inhibitor concentration response curves for assay and screen validation. (A, B) Concentration response curves of 2 (compounds 1 and 2, respectively) of the 10 reference compounds used to validate the assay for high-throughput screening. Duplicate titration plates were run over 3 days to ensure reproducibility of their IC 50 values. In addition, titrations of these compounds were included in each daily run of the screen, as quality control plates, to monitor assay integrity. Each curve was fitted to the standard four-parameter logistic equation for four replicate data points. (C, D) Concentration response curves of two inhibitors (compounds 3 and 4, respectively) identified in the initial diversity (4798 compounds) and virtual library (7095 compounds) sets used for screen validation. Each curve was fitted to the standard four-parameter logistic equation for three replicate data points.
inhibitors were used as quality control (QC) compounds to monitor the integrity of daily screen runs. Prior to initiating the full HTS, a pilot screen of a small set of diverse compounds (4798) was conducted at 12.3 mM in duplicate to allow us to gauge screening performance under fully automated conditions, by assessing assay data reproducibility and robustness. At a 40% inhibition threshold, the observed hit rate was 1.1%, and the Z′ calculated from the plate high and low signal controls was ~0.8, which was consistent with bench validation. Overall, the hit rate and Z′ were within acceptable limits for an HTS campaign. In addition, we screened a set of 7095 virtual library compounds at 12.3 mM in duplicate. These were compounds that were selected from the BMS compound inventory via computational docking studies focused on the PTP-g active site. These studies used a homology model of PTP-g that was based on a published x-ray crystal structure of PTP-m. 12 Compounds that generated mean inhibition ≥ 40% were selected as hits (hit rate ~0.9). Subsequently, 95 of these compounds were titrated to determine their IC 50 values. Of this list, IC 50 values were generated for 70 of these compounds, which exhibited concentration responses. Examples of the concentration response curves of two of the inhibitors (compound 3 and compound 4) and their IC 50 values are shown in Figure 6C ,D.
HTS and hit confirmation
The high-throughput screen was executed on a diverse subset of the BMS compound collection in a low-volume 384-well format as described in Materials and Methods. The statistical measure of assay robustness, Z′ value for each plate, was calculated from the plate high and low signal controls. Overall, the mean Z′ of plate controls across the entire screen was 0.81 ± 0.04 ( Fig. 7A) , which is indicative of a robust high-throughput screen. Other screen reliability statistics, such as number of hits per well and number of hits per plate (data not shown), were consistent with a robust screen. For an HTS, these parameters are generally expected to be randomly distributed unless one encounters structurally related set of compounds or some sort of systematic error in the process. There were a few plates that had an unusually high number of hits per plate, which were later found to be a library of compounds with similar structures.
The distribution of activity (% inhibition values) of representative compounds from the first 1900 plates is shown in Figure  7B for illustration purposes. As expected, the majority of the compounds were inactive, with a mean % inhibition of the distribution activity of 8.7 ± 17.7. Overall, the HTS generated a higher hit rate than the pilot screen, so the threshold for hit selection was increased from 40% (pilot screen) to 60% inhibition, approximately the mean plus 3 × SD of the distribution. On the basis of this threshold, 26 765 compounds (2.7% hit rate) were selected as hits. Of this number, 26 235 compounds were available for confirmation testing in triplicate at 12.3 mM. Compounds that resulted in mean triplicate inhibition of ≥60% (13 194) were selected as actives and further tested for interference in a null assay. Here, the primary receptor PTP-g enzyme reaction was carried out and terminated before compounds were added, followed by the protease development reaction, to independently determine interference in the FRET assay. Thus, any compound that showed apparent RPTP-g inhibition was either directly interfering with the assay signal or inhibiting the protease in the development reagent. About 9% of the compounds (1152) showed inhibition of ≥20% in the null assay and were designated as assay interference and eliminated for further consideration. The remaining 12 042 compounds, confirmed actives, were triaged and clustered. In the triaging process, 4491 of these compounds were flagged as "questionable" based on the following criteria: cLogP ≥8.0, rotatable bonds ≥15, H-bond donors ≥7, H-bond acceptors ≥309, molecular weight ≥800, and other exclusion filters. The entire list was clustered using Signpost Clustering with a 0.65 similarity cutoff. The most active sample(s) not flagged as questionable were selected from each cluster. However, if all compounds in a cluster were questionable, no compound was selected. Also, more than one compound was selected from clusters with ≥20 members. In addition, compounds that appeared as singletons and were not designated questionable were selected. The observed hit rate of 2.7% was higher than what we generally expect (~1%) for our HTS campaigns. This may be attributed, in part, to the aforementioned 9% false-positive rate resulting from assay interference and >4000 questionable compounds. In addition, general assay noise and nonspecific inhibitors that elicit their activities via aggregation could have contributed to this high hit rate.
In all, 2226 compounds were recommended for IC 50 determination to evaluate their potencies. From this list, 2170 compounds were obtained, and triplicate CRCs were generated for IC 50 determination. To obtain selectivity information, IC 50 values were also determined for two other phosphatase enzymes, PTP-1B and CD45, using the Z′-LYTE assay. A total of 257 compounds with 5-to 10-fold or more preference, based on IC 50 values, for receptor PTP-g over PTP-1B and CD45 were classified as selective. Among these, 147 compounds with IC 50 >25 mM and/or Hill slopes >3 were deprioritized and an additional 18 removed for chemical intractability. After the selectivity profile and chemical intractability assessment, 129 compounds that displayed potencies of <1 mM (13), 1-10 mM (82), and 10-25 mM (34) were prioritized for further characterization in biochemical and direct binding assays. The structure and concentration response curve of one of the initial leads, 3-(3,4-dichlorobenzylthio)thiophene-2-carboxylic acid, is shown in Figure 8 .
DISCUSSION
In this study, we have demonstrated that, although the Z′-LYTE technology is typically used for kinase assays, the system can be modified and used for the identification of phosphatase inhibitors via HTS. The assay was designed and optimized to screen a subset of the BMS compound collection to identify diverse chemotypes with selectivity for receptor PTP-g in a low-volume 384-well format. Compounds initially identified as hits were run in a null assay to eliminate those whose activities were due to interference in the fluorescent assay. The remaining compounds were triaged and clustered based on their chemical properties and structural similarities, respectively. Selectivity profile and chemical intractability assessment were subsequently completed for 257 selected compounds. The 129 compounds that were identified as selective receptor PTP-g inhibitors were prioritized for further characterization in biochemical and direct binding assays. The HTS identified several lead chemotypes with ≥5-fold selectivity for receptor PTP-g over PTP-1B and CD45. One of the initial leads, 3-(3,4-dichlorobenzylthio)thiophene-2-carboxylic acid, exhibited direct binding with nuclear magnetic resonance (NMR) and thermal shift assays (P. A. McDonnell and J. Yanchunas, personal communication, 2006). This compound showed receptor PTP-g selectivity of 14-and >24-fold over PTP-1B and CD45, respectively (Fig. 8 ). This lead was subsequently found to be a time-dependent, reversible, and competitive inhibitor of receptor PTP-g. The details of the structure-activity relationship around this chemotype and the x-ray co-crystal structure of the catalytic domain of the human receptor PTP-g with 3-(3,4-dichlorobenzylthio)thiophene-2-carboxylic acid bound will be published elsewhere. Finally, this chemotype enabled the initiation of a medicinal chemistry program. 
